Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib or Lenalidomide with Bendamustine-Rituximab in High-Risk Follicular Lymphoma
NCT01216683Phase 2Completed
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Start
- Feb 2011
- Primary completion
- Dec 2019
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib, lenalidomide in follicular lymphoma (FL), sponsored by ECOG-ACRIN Cancer Research Group. Started Feb 2011; status: completed.
02
Drugs
bortezomiblenalidomide
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT01216683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01216683.